AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2699 companies scored · 2026-10-16 run in progress: 1092 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-15 run
Companies scored 2699 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.30% Alpha · 90D
Long–short spread +5.08% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 424 ▼ 506 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

303 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
201 SGMTSagimet Biosciences Inc. Life Sciences 0.35 $469M Unlock rating and forecasts
202 ARVNARVINAS, INC. Life Sciences 0.25 $468M Unlock rating and forecasts
203 ALLOAllogene Therapeutics, Inc. Life Sciences 0.05 $463M Unlock rating and forecasts
204 AUTLAutolus Therapeutics plc Life Sciences 0.32 $458M Neutral -0.09% -0.14% ▼ 2
205 RGNXREGENXBIO Inc. Life Sciences 0.03 $454M Unlock rating and forecasts
206 PROKPROKIDNEY CORP. Life Sciences 0.00 $442M Unlock rating and forecasts
207 OVIDOvid Therapeutics Inc. Life Sciences 0.06 $441M Unlock rating and forecasts
208 ENTXEntera Bio Ltd. Life Sciences 0.26 $433M Unlock rating and forecasts
209 NIKANIKA PHARMACEUTICALS, INC Life Sciences 0.17 $431M Unlock rating and forecasts
210 PRTAPROTHENA CORP PUBLIC LTD CO Life Sciences 0.27 $430M Unlock rating and forecasts
211 TLRYTilray Brands, Inc. Life Sciences 0.01 $428M Neutral -0.20% -0.79% ▲ 1
212 CAPRCAPRICOR THERAPEUTICS, INC. Life Sciences 0.44 $423M Unlock rating and forecasts
213 ZURAZura Bio Ltd Life Sciences 0.24 $423M Unlock rating and forecasts
214 ASMBASSEMBLY BIOSCIENCES, INC. Life Sciences 0.06 $419M Unlock rating and forecasts
215 TKNOAlpha Teknova, Inc. Life Sciences 0.46 $418M Unlock rating and forecasts
216 MYGNMYRIAD GENETICS INC Life Sciences 0.39 $416M Unlock rating and forecasts
217 TECXTectonic Therapeutic, Inc. Life Sciences 0.02 $410M Unlock rating and forecasts
218 EIKNEikon Therapeutics, Inc. Life Sciences 0.32 $408M Unlock rating and forecasts
219 ADXNAddex Therapeutics Ltd. Life Sciences 0.02 $392M Unlock rating and forecasts
220 SPRYARS Pharmaceuticals, Inc. Life Sciences 0.25 $391M Neutral +0.99% +0.06% ·
221 CANFCan-Fite BioPharma Ltd. Life Sciences 0.17 $383M Unlock rating and forecasts
222 EDITEditas Medicine, Inc. Life Sciences 0.21 $375M Unlock rating and forecasts
223 KYTXKyverna Therapeutics, Inc. Life Sciences 0.62 $369M Unlock rating and forecasts
224 EBSEmergent BioSolutions Inc. Life Sciences 0.55 $368M Unlock rating and forecasts
225 GALTGALECTIN THERAPEUTICS INC Life Sciences 0.07 $367M Neutral +0.22% -0.26% ·
226 FENCFENNEC PHARMACEUTICALS INC. Life Sciences 0.35 $363M Unlock rating and forecasts
227 RLMDRELMADA THERAPEUTICS, INC. Life Sciences 0.36 $346M Unlock rating and forecasts
228 PRLDPrelude Therapeutics Inc Life Sciences 0.03 $343M Unlock rating and forecasts
229 CCCCC4 Therapeutics, Inc. Life Sciences 0.31 $342M Unlock rating and forecasts
230 IRDOpus Genetics, Inc. Life Sciences 0.29 $337M Unlock rating and forecasts
231 ENTAENANTA PHARMACEUTICALS INC Life Sciences 0.52 $334M Unlock rating and forecasts
232 IKTInhibikase Therapeutics, Inc. Life Sciences 0.07 $333M Unlock rating and forecasts
233 CYPHCYPHERPUNK TECHNOLOGIES INC. Life Sciences 0.17 $325M Neutral 0.00% +0.04% ·
234 ARCTArcturus Therapeutics Holdings Inc. Life Sciences 0.17 $320M Unlock rating and forecasts
235 TTRXTurn Therapeutics Inc. Life Sciences 0.71 $316M Unlock rating and forecasts
236 AGENAGENUS INC Life Sciences 0.59 $301M Unlock rating and forecasts
237 ARTVArtiva Biotherapeutics, Inc. Life Sciences 0.23 $296M Unlock rating and forecasts
238 USNAUSANA HEALTH SCIENCES INC Life Sciences 0.59 $282M Unlock rating and forecasts
239 FULCFulcrum Therapeutics, Inc. Life Sciences 0.01 $280M Unlock rating and forecasts
240 SRZNSurrozen, Inc./DE Life Sciences 0.01 $279M Unlock rating and forecasts
241 OCGNOcugen, Inc. Life Sciences 0.42 $276M Unlock rating and forecasts
242 IPSCCentury Therapeutics, Inc. Life Sciences 0.37 $272M Unlock rating and forecasts
243 NWBONORTHWEST BIOTHERAPEUTICS INC Life Sciences 0.00 $270M Neutral -0.07% -0.32% ·
244 ELTPELITE PHARMACEUTICALS INC /NV/ Life Sciences 0.35 $267M Unlock rating and forecasts
245 CATXPerspective Therapeutics, Inc. Life Sciences 0.11 $267M Unlock rating and forecasts
246 PALIPALISADE BIO, INC. Life Sciences 0.13 $265M Unlock rating and forecasts
247 CABACabaletta Bio, Inc. Life Sciences 0.05 $263M Unlock rating and forecasts
248 ACBAURORA CANNABIS INC Life Sciences 0.17 $260M Neutral +0.07% +0.16% ·
249 LABSTANDARD BIOTOOLS INC. Life Sciences 0.21 $259M Unlock rating and forecasts
250 VNDAVanda Pharmaceuticals Inc. Life Sciences 0.39 $255M Unlock rating and forecasts
201–250 of 303 Previous Next
Since the previous run

Rating changes

▲ 424▼ 506
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.